Drägerwerk AG & Co. KGaA – 2030‑Ambition und Marktreaktion
Drägerwerk AG & Co. KGaA presented its 2030 ambition during a capital markets day held in Lübeck on 18 November 2026. The German health‑care‑equipment manufacturer announced that it targets net sales of EUR 4.5 billion and an EBIT margin of 10 %–12 % by 2030, an increase of roughly EUR 1 billion compared with 2025 figures.
Key elements of the 2030 strategy
| Item | 2025 (est.) | 2030 target |
|---|---|---|
| Net sales | ~EUR 3.5 billion | EUR 4.5 billion |
| EBIT margin | 6.7 % | 10 %–12 % |
| Contribution of Medizintechnik | ~EUR 2.0 billion | ~EUR 2.5 billion |
| Contribution of Sicherheitstechnik | ~EUR 1.5 billion | ~EUR 2.0 billion |
The company plans to achieve this growth through integrated solutions and recurring revenue models in its medical division, and by expanding its safety‑technology business in selected high‑growth markets. It also highlighted a strong balance sheet and disciplined capital allocation as foundations for the targeted profitability.
Stock market reaction
The announcement lifted Drägerwerk’s share price sharply:
- Early trading: The share opened at EUR 117.80, up 5.6 % from the previous close.
- Peak: By the end of September 2026, the stock had reached a record high of EUR 125.40.
- Year‑to‑date performance: The share has risen almost 70 % since the beginning of the calendar year, driven by the optimism surrounding the 2030 outlook.
Analysts have praised the company’s clear mid‑term targets. A trader noted that the 2030 revenue goal of EUR 4.5 billion exceeds the market’s prior expectation of EUR 4.3 billion, and that the projected EBIT margin improvement to the 10 %–12 % range is a significant upside.
Context within the health‑care‑equipment sector
Drägerwerk operates in the broader Health Care Equipment & Supplies sector and is listed on Xetra under the ticker DE0005550636. With a market capitalisation of approximately EUR 1.59 billion and a price‑earnings ratio of 8.94, the stock is considered a mid‑cap play with a solid earnings base. The company’s product portfolio spans ventilators, monitoring equipment, transport incubators, anesthesia machines, surgical lights, ward equipment, home‑care systems, and safety‑equipment for industry, mining, firefighting, and aviation.
The recent positive market reaction reflects confidence in Drägerwerk’s ability to translate its 2030 ambition into tangible revenue and profitability gains, supported by its diversified product range and disciplined financial management.




